{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T00:02:12Z","timestamp":1792627332518,"version":"4.5.0"},"reference-count":80,"publisher":"Informa UK Limited","issue":"8","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Review of Neurotherapeutics"],"published-print":{"date-parts":[[2024,8,2]]},"DOI":"10.1080\/14737175.2024.2370349","type":"journal-article","created":{"date-parts":[[2024,7,24]],"date-time":"2024-07-24T04:04:46Z","timestamp":1721793886000},"page":"761-771","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":20,"title":["An overview of the currently available and emerging long-acting formulations of risperidone for schizophrenia and bipolar disorder"],"prefix":"10.1080","volume":"24","author":[{"given":"Justin","family":"Faden","sequence":"first","affiliation":[{"name":"Lewis Katz School of Medicine, Temple University, Philadelphia, PA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camila","family":"Ramirez","sequence":"additional","affiliation":[{"name":"Lewis Katz School of Medicine, Temple University, Philadelphia, PA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanessa","family":"Martinez","sequence":"additional","affiliation":[{"name":"Lewis Katz School of Medicine, Temple University, Philadelphia, PA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leslie","family":"Citrome","sequence":"additional","affiliation":[{"name":"New York Medical College, Valhalla, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2024,7,23]]},"reference":[{"key":"e_1_3_4_3_1","doi-asserted-by":"publisher","DOI":"10.1586\/14737175.2013.811984"},{"key":"e_1_3_4_4_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2020.177901"},{"key":"e_1_3_4_5_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2016.16050503"},{"key":"e_1_3_4_6_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v63n1007"},{"key":"e_1_3_4_7_1","doi-asserted-by":"publisher","DOI":"10.1002\/wps.20060"},{"key":"e_1_3_4_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.psychres.2015.04.047"},{"key":"e_1_3_4_9_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.7090su1cj"},{"key":"e_1_3_4_10_1","doi-asserted-by":"publisher","DOI":"10.1093\/schbul\/sbab063"},{"key":"e_1_3_4_11_1","doi-asserted-by":"publisher","DOI":"10.1192\/bjpo.bp.116.002766"},{"key":"e_1_3_4_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/eip.13098"},{"key":"e_1_3_4_13_1","doi-asserted-by":"publisher","DOI":"10.1097\/NMD.0000000000001151"},{"key":"e_1_3_4_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2023.04.030"},{"key":"e_1_3_4_15_1","doi-asserted-by":"publisher","DOI":"10.1192\/bjo.2018.17"},{"key":"e_1_3_4_16_1","doi-asserted-by":"publisher","DOI":"10.1093\/schbul\/sbx176"},{"key":"e_1_3_4_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.schres.2016.09.029"},{"key":"e_1_3_4_18_1","first-page":"32","article-title":"Managing first-episode psychosis: an early stage of schizophrenia with distinct treatment needs: minimize duration of untreated psychosis; aim for remission","volume":"14","author":"Gardner KN","year":"2015","unstructured":"Gardner KN, Nasrallah HA. Managing first-episode psychosis: an early stage of schizophrenia with distinct treatment needs: minimize duration of untreated psychosis; aim for remission. Curr Psychiatry. 2015;14:32\u201341.","journal-title":"Curr Psychiatry"},{"key":"e_1_3_4_19_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.npp.1301347"},{"key":"e_1_3_4_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2215-0366(20)30264-9"},{"key":"e_1_3_4_21_1","doi-asserted-by":"publisher","DOI":"10.1002\/wps.20699"},{"key":"e_1_3_4_22_1","doi-asserted-by":"publisher","DOI":"10.1017\/S0033291717000873"},{"issue":"5","key":"e_1_3_4_23_1","first-page":"3","article-title":"Epidemiology, clinical consequences, and psychosocial treatment of nonadherence in schizophrenia","volume":"67","author":"Leucht S","year":"2006","unstructured":"Leucht S, Heres S. Epidemiology, clinical consequences, and psychosocial treatment of nonadherence in schizophrenia. J Clin Psychiatry. 2006;67(Suppl 5):3\u20138.","journal-title":"J Clin Psychiatry"},{"key":"e_1_3_4_24_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2023.18588"},{"key":"e_1_3_4_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2016.01.002"},{"key":"e_1_3_4_26_1","doi-asserted-by":"publisher","DOI":"10.1080\/14656566.2021.1882996"},{"key":"e_1_3_4_27_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40263-019-00629-z"},{"key":"e_1_3_4_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2215-0366(21)00039-0"},{"key":"e_1_3_4_29_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2017.1322"},{"key":"e_1_3_4_30_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2020.2076"},{"key":"e_1_3_4_31_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40263-021-00815-y"},{"key":"e_1_3_4_32_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41380-023-02175-z"},{"key":"e_1_3_4_33_1","unstructured":"Risperdal Consta (risperidone). Package Insert. Janssen Pharmaceuticals; 2021 Feb [cited 2024 Apr 27]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/020272Orig1s083 020588Orig1s071 021444Orig1s057 021346Orig1s061lbl.pdf"},{"key":"e_1_3_4_34_1","doi-asserted-by":"publisher","DOI":"10.1093\/schbul\/13.2.261"},{"key":"e_1_3_4_35_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.160.6.1125"},{"key":"e_1_3_4_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopsych.2010.01.015"},{"key":"e_1_3_4_37_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399-5618.2009.00761.x"},{"key":"e_1_3_4_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.euroneuro.2012.03.004"},{"key":"e_1_3_4_39_1","unstructured":"Rykindo (risperidone). Package Insert. Shandong Luye Pharmaceutical Co; 2023 Jan [cited 2024 Apr 27]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/212849s000lbl.pdf"},{"key":"e_1_3_4_40_1","unstructured":"U.S. FDA. New drug application approval letter. Rykindo (risperidone). [cited 2024 Apr 26]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/appletter\/2023\/212849Orig1s000ltr.pdf"},{"key":"e_1_3_4_41_1","volume-title":"Poster presented at: Psych Congress","author":"Wang W","unstructured":"Wang W, Wang X, Zhang Y, et al. Population pharmacokinetics for switching from oral or long-acting injectable risperidone to Rykindo (risperidone) for extended-release injectable suspension, a novel long-acting injectable, in patients with schizophrenia. In: Poster presented at: Psych Congress; Nashville, TN; 2023 Sep 6\u201310."},{"key":"e_1_3_4_42_1","unstructured":"U.S. FDA. New Drug Application Approval Letter. Risvan (risperidone ISM). [cited 2024 Apr 26]. Available from: https:\/\/www.rovi.es\/en\/content\/rovi-receives-fdas-approval-risvanr-treatment-schizophrenia"},{"key":"e_1_3_4_43_1","unstructured":"Risvan (risperidone). Package insert. Rovi S.A; 2024 [cited 2024 Apr 27]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/214835s000lbl.pdf"},{"key":"e_1_3_4_44_1","unstructured":"Okedi (risperidone). Package insert. Rovi S.A; 2024 [cited 2024 Apr 27]. Available from: https:\/\/pdf.hres.ca\/dpd_pm\/00075022.PDF"},{"key":"e_1_3_4_45_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41537-020-00127-y"},{"key":"e_1_3_4_46_1","first-page":"218","volume-title":"ECDEU assessment manual for psychopharmacology \u2014 revised","author":"Guy W","year":"1976","unstructured":"Guy W. Clinical Global Impression (CGI). In: ECDEU assessment manual for psychopharmacology \u2014 revised. Rockville (MD): National Institute of Mental Health; 1976. p. 218\u2013222."},{"key":"e_1_3_4_47_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.schres.2021.11.030"},{"key":"e_1_3_4_48_1","doi-asserted-by":"publisher","DOI":"10.2147\/NDT.S392351"},{"key":"e_1_3_4_49_1","unstructured":"Perseris (risperidone). Package insert. North Chesterfield (VA): Indivior Inc; 2022 [cited 2024 Apr 27]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/210655s000lbl.pdf"},{"key":"e_1_3_4_50_1","doi-asserted-by":"publisher","DOI":"10.1097\/JCP.0000000000000479"},{"key":"e_1_3_4_51_1","doi-asserted-by":"publisher","DOI":"10.1097\/JCP.0000000000001076"},{"key":"e_1_3_4_52_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.schres.2016.03.020"},{"key":"e_1_3_4_53_1","doi-asserted-by":"publisher","DOI":"10.2147\/PPA.S202173"},{"key":"e_1_3_4_54_1","unstructured":"Uzedy (risperidone) extended-release injectable suspension. Package insert. Parsippany (NJ): Teva Neuroscience Inc; 2023 [cited 2024 Apr 27]. Available from: https:\/\/www.uzedyhcp.com\/globalassets\/uzedy\/prescribing-information.pdf"},{"key":"e_1_3_4_55_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2215-0366(23)00288-2"},{"key":"e_1_3_4_56_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40263-020-00735-3"},{"key":"e_1_3_4_57_1","volume-title":"Presented at: American Society of Clinical Psychopharmacology","author":"Weiden P","unstructured":"Weiden P, Citrome L, Watkins G, et al. Can an implantable device deliver a year of maintenance risperidone? Results from a phase 1PK\/safety study evaluating 6 and 12-month versions of the DLP-114 device in schizophrenia. Presented at: American Society of Clinical Psychopharmacology; Miami, Fl; 2024 May 27\u201331."},{"key":"e_1_3_4_58_1","unstructured":"Braeburn Pharmaceuticals Phase 2\/3 update. 2024Apr 26. Available from: https:\/\/www.prnewswire.com\/news-releases\/braeburn-pharmaceuticals-achieves-primary-endpoint-in-pivotal-phase-23-study-of-bb0817-risperidone-6-month-implant-for-treatment-of-schizophrenia-300446397.html"},{"key":"e_1_3_4_59_1","volume-title":"Poster session presented at: Neuroscience Education Institute (NEI) Congress","author":"Weiden P","unstructured":"Weiden P, Watkins G, Liu B, et al. Feasibility of a risperidone implant for the maintenance treatment of schizophrenia for up to 12 months after a single administration. In: Poster session presented at: Neuroscience Education Institute (NEI) Congress; (CO) Springs (CO); [2023 Nov 9\u201312]."},{"key":"e_1_3_4_60_1","unstructured":"Lyndra [Internet]. Watertown (MA). [cited 2024 Apr 26].Available from: https:\/\/lyndra.com\/platform\/"},{"key":"e_1_3_4_61_1","unstructured":"Lyndra therapeutics announces positive data from pivotal phase 3 study with oral weekly risperidone (LYN-005) for Schizophrenia. [cited 2024 Apr 18]. Available from: https:\/\/www.businesswire.com\/news\/home\/20240104163052\/en\/"},{"key":"e_1_3_4_62_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.schres.2016.07.018"},{"key":"e_1_3_4_63_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2015.0270"},{"key":"e_1_3_4_64_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2020.20071120"},{"key":"e_1_3_4_65_1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2017-00359"},{"issue":"11","key":"e_1_3_4_66_1","first-page":"1845","article-title":"A comparison of low dose methotrexate bioavailability: oral solution, oral tablet, subcutaneous and intramuscular dosing","volume":"20","author":"Jundt JW","year":"1993","unstructured":"Jundt JW, Browne BA, Fiocco GP, et al. A comparison of low dose methotrexate bioavailability: oral solution, oral tablet, subcutaneous and intramuscular dosing. J Rheumatol. 1993;20(11):1845\u20131849.","journal-title":"J Rheumatol"},{"key":"e_1_3_4_67_1","doi-asserted-by":"publisher","DOI":"10.2147\/PPA.S87271"},{"key":"e_1_3_4_68_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780330112"},{"key":"e_1_3_4_69_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-023-02455-8"},{"key":"e_1_3_4_70_1","volume-title":"Poster presented at: American Society of Clinical Psychopharmacology","author":"Citrome L","unstructured":"Citrome L, Correll C, Mattingly G, et al. Key characteristics of the long-acting injectable atypical antipsychotic aripiprazole lauroxil for the treatment of adults with schizophrenia. In: Poster presented at: American Society of Clinical Psychopharmacology; Miami, Fl; [2024 May 27\u201331]."},{"key":"e_1_3_4_71_1","doi-asserted-by":"publisher","DOI":"10.2147\/PPA.S410028"},{"key":"e_1_3_4_72_1","doi-asserted-by":"publisher","DOI":"10.2147\/PPA.S349460"},{"key":"e_1_3_4_73_1","doi-asserted-by":"publisher","DOI":"10.2147\/PPA.S187120"},{"key":"e_1_3_4_74_1","doi-asserted-by":"publisher","DOI":"10.2147\/PPA.S192418"},{"key":"e_1_3_4_75_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2022.02.003"},{"key":"e_1_3_4_76_1","doi-asserted-by":"publisher","DOI":"10.1017\/S1092852921000249"},{"key":"e_1_3_4_77_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1742-1241.2009.02240.x"},{"key":"e_1_3_4_78_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40120-015-0030-4"},{"key":"e_1_3_4_79_1","doi-asserted-by":"publisher","DOI":"10.1080\/13696998.2020.1754229"},{"key":"e_1_3_4_80_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12888-022-04075-y"},{"key":"e_1_3_4_81_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.psychres.2022.114581"},{"key":"e_1_3_4_82_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ps.201800130"}],"container-title":["Expert Review of Neurotherapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14737175.2024.2370349","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,16]],"date-time":"2024-10-16T10:31:45Z","timestamp":1729074705000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14737175.2024.2370349"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,23]]},"references-count":80,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2024,8,2]]}},"alternative-id":["10.1080\/14737175.2024.2370349"],"URL":"https:\/\/doi.org\/10.1080\/14737175.2024.2370349","relation":{},"ISSN":["1473-7175","1744-8360"],"issn-type":[{"value":"1473-7175","type":"print"},{"value":"1744-8360","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,23]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iern20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iern20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2024-04-29","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-06-16","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-07-23","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}